Monosodium urate (crystals)
| Code | Size | Price |
|---|
| AG-CR1-3950-M002 | 2 mg | £80.00 |
Quantity:
| AG-CR1-3950-2002 | 2 x 2 mg | £125.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
Ambient
Storage:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
MSU (crystals); Uric acid (crystals)
Appearance:
Solid crystals. Solution may appear as a slightly hazy suspension.
CAS:
1198-77-2
EClass:
32160000
Endotoxin:
<0.001EU/µg purified protein (LAL test; Lonza).
Form (Short):
liquid
Handling Advice:
Vortex before use.
InChi:
InChI=1S/C5H4N4O3.Na/c10-3-1-2(7-4(11)6-1)8-5(12)9-3;/h(H4,6,7,8,9,10,11,12);/q;+1/p-1
InChiKey:
NAFSTSRULRIERK-UHFFFAOYSA-M
Long Description:
Chemical. CAS: 1198-77-2. Formula: C5H3N4O3 . Na. MW: 167.1 . 23.0. NLRP3/NALP3 inflammasome activator. Specially crystallized and tested for biological activity. Stimulates the caspase-1 activating NLRP3/NALP3 inflammasome, resulting in the production of active IL-1beta and IL-18.
MDL:
MFCD00067310
Molecular Formula:
C5H3N4O3 . Na
Molecular Weight:
167.1 . 23.0
Package Type:
Vial
Product Description:
NLRP3/NALP3 inflammasome activator. Specially crystallized and tested for biological activity. Stimulates the caspase-1 activating NLRP3/NALP3 inflammasome, resulting in the production of active IL-1beta and IL-18.
SMILES:
[Na+].[O-]C1=NC(=O)NC2=C1NC(=O)N2
Solubility Chemicals:
Not soluble in PBS. Reconstitute 2mg of MSU in 100µl PBS to obtain a 20mg/ml suspension.
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Gout-associated uric acid crystals activate the NALP3 inflammasome: F. Martinon, et al.; Nature 440, 237 (2006) | Malarial hemozoin activates the NLRP3 inflammasome through Lyn and Syk kinases: M.T. Shio, et al.; PLoS Pathog. 5, e1000559 (2009) | Crystals of monosodium urate monohydrate enhance lipopolysaccharide-induced release of interleukin 1 beta by mononuclear cells through a caspase 1-mediated process: E.J. Giamarellos-Bourboulis, et al.; Ann. Rheum. Dis. 68, 273 (2009) | Monosodium urate crystals in inflammation and immunity: Y. Shi, et al.; Immunol. Rev. 233, 203 (2010) | RIP3-mediated necrotic cell death accelerates systematic inflammation and mortality: L. Meng, et al.; PNAS 112, 11007 (2015) | Shigella hijacks the glomulin-cIAPs-inflammasome axis to promote inflammation: S. Suzuki, et al.; EMBO Rep.19, 89 (2018) | Calcium phosphate particles stimulate interleukin-1beta release from human vascular smooth muscle cells: A role for spleen tyrosine kinase and exosome release: Y. Dautova, et al.; J. Mol. Cell Cardiol. 115, 82 (2018) | Cutting Edge: G Protein Subunit beta 1 Negatively Regulates NLRP3 Inflammasome Activation: T. Murakami, et al.; J. Immunol. 202, 1942 (2019) | Expression of a PYCARD/ASC variant lacking exon 2 in Japanese patients with palindromic rheumatism increases interleukin-1beta secretion: Y. Suganuma, et al.; Asian Pac. J. Allergy Immunol. (Epub ahead of print) (2019)
Related Products
| Product Name | Product Code | Supplier | Colchicine | AG-CN2-0048 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Parthenolide | AG-CN2-0455 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arglabin | AG-CN2-0458 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| BAY 11-7082 | AG-CR1-0013 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||